Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Clinical Research and Equipment Industry Analysis

UpdatedSep 25, 2025
DataAggregated Company Financials
Companies7
  • 7D-4.0%
  • 3M-5.9%
  • 1Y-9.0%
  • YTDn/a

Over the last 7 days, the Clinical Research and Equipment industry has dropped 4.0%, driven by Lonza Group declining 3.9%. Overall the industry is down 9.0% in 12 months. Looking forward, earnings are forecast to grow by 21% annually.

Industry Valuation and Performance

Has the Swiss Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 26 Sep 2025CHF 49.2bCHF 10.6bCHF 1.1b33x44.6x4.6x
Sun, 24 Aug 2025CHF 53.7bCHF 10.7bCHF 1.1b36.5x48.7x5x
Tue, 22 Jul 2025CHF 53.1bCHF 10.1bCHF 1.0b33x51.1x5.3x
Thu, 19 Jun 2025CHF 52.5bCHF 10.1bCHF 1.0b33.3x50.5x5.2x
Sat, 17 May 2025CHF 53.3bCHF 10.1bCHF 1.0b32.9x51.3x5.3x
Mon, 14 Apr 2025CHF 48.0bCHF 10.1bCHF 1.0b28.1x46.8x4.8x
Wed, 12 Mar 2025CHF 51.1bCHF 10.1bCHF 1.0b28.7x48.9x5x
Fri, 07 Feb 2025CHF 58.6bCHF 10.1bCHF 1.0b36.7x58.2x5.8x
Sun, 05 Jan 2025CHF 52.7bCHF 10.2bCHF 943.5m36x55.8x5.2x
Tue, 03 Dec 2024CHF 53.4bCHF 10.2bCHF 943.7m40.8x56.6x5.2x
Thu, 31 Oct 2024CHF 54.5bCHF 10.2bCHF 943.4m41.8x57.8x5.3x
Sat, 28 Sep 2024CHF 55.9bCHF 10.2bCHF 943.4m43.2x59.3x5.5x
Mon, 26 Aug 2024CHF 58.1bCHF 10.2bCHF 936.8m45.6x62x5.7x
Wed, 24 Jul 2024CHF 55.4bCHF 10.3bCHF 1.0b48x55.3x5.4x
Fri, 21 Jun 2024CHF 51.7bCHF 10.3bCHF 1.0b44.4x51.5x5x
Sun, 19 May 2024CHF 56.1bCHF 10.3bCHF 1.0b46x56x5.5x
Tue, 16 Apr 2024CHF 55.9bCHF 10.3bCHF 1.0b44.2x55.7x5.4x
Thu, 14 Mar 2024CHF 52.5bCHF 10.2bCHF 1.0b44.5x52.3x5.1x
Sat, 10 Feb 2024CHF 48.1bCHF 10.2bCHF 1.0b42.5x47.2x4.7x
Mon, 08 Jan 2024CHF 40.2bCHF 9.8bCHF 1.5b30.7x26.9x4.1x
Wed, 06 Dec 2023CHF 39.4bCHF 9.8bCHF 1.5b28.9x26.4x4x
Fri, 03 Nov 2023CHF 37.8bCHF 9.8bCHF 1.5b26.4x25.3x3.9x
Sun, 01 Oct 2023CHF 46.5bCHF 9.8bCHF 1.5b32.2x31.2x4.8x
Tue, 29 Aug 2023CHF 52.0bCHF 9.8bCHF 1.5b36x34.8x5.3x
Thu, 27 Jul 2023CHF 52.3bCHF 9.8bCHF 1.5b35.8x33.8x5.3x
Sat, 24 Jun 2023CHF 55.2bCHF 9.7bCHF 1.6b34.3x33.7x5.7x
Mon, 22 May 2023CHF 60.8bCHF 9.7bCHF 1.6b39x37.2x6.3x
Wed, 19 Apr 2023CHF 61.4bCHF 9.7bCHF 1.7b42.6x36.8x6.3x
Fri, 17 Mar 2023CHF 56.6bCHF 9.7bCHF 1.7b41x34.2x5.9x
Sun, 12 Feb 2023CHF 57.2bCHF 9.6bCHF 1.6b33.2x35x6x
Tue, 10 Jan 2023CHF 51.2bCHF 9.2bCHF 1.3b37.7x38.5x5.6x
Thu, 08 Dec 2022CHF 51.3bCHF 9.2bCHF 1.3b38.2x38.6x5.6x
Sat, 05 Nov 2022CHF 50.4bCHF 9.2bCHF 1.3b39.1x37.9x5.5x
Mon, 03 Oct 2022CHF 50.6bCHF 9.2bCHF 1.3b39.7x39.1x5.5x
Price to Earnings Ratio

39.1x


Total Market Cap: CHF 50.6bTotal Earnings: CHF 1.3bTotal Revenue: CHF 9.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Clinical Research and Equipment Industry Price to Earnings3Y Average 45.1x202320242025
Current Industry PE
  • Investors are relatively neutral on the Swiss Life Sciences Tools and Services industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 45.1x.
  • The 3-year average PS ratio of 5.3x is higher than the industry's current PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have declined 5.2% per year over the last three years.
  • Meanwhile revenues for these companies have grown 5.1% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Swiss Clinical Research and Equipment compare with similar industries?

CH Market-0.40%
Healthcare-0.62%
Life Sciences-3.97%
Clinical Research and Equipment-3.97%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
XLS Xlife SciencesCHF 21.004.5%
+CHF 5.2m		-31.8%PE3.9x

Latest News

PPGN
CHF 24.00
PolyPeptide Group
7D
-8.0%
1Y
-24.1%

PolyPeptide Group (VTX:PPGN) Is Carrying A Fair Bit Of Debt

Sep 25
PolyPeptide Group (VTX:PPGN) Is Carrying A Fair Bit Of Debt
XLS
CHF 21.00
Xlife Sciences
7D
4.5%
1Y
-31.8%
LONN
CHF 518.00
Lonza Group
7D
-4.7%
1Y
-4.1%

Vacaville And Visp Facilities Will Secure Future Biologics Demand

Given the absence of analyst reasoning, the consensus analyst price target for Lonza Group saw only a marginal increase from CHF665.36 to CHF676.18 alongside minimal changes in key valuation metrics such as future P/E and discount rate, indicating steady market expectations and a broadly unchanged fair value outlook. What's in the News Lonza entered a seven-year manufacturing agreement with Avidity Biosciences for commercial drug substance and product, with a minimum purchase commitment of approximately $620 million between 2026 and 2028.
BANB
CHF 58.15
Bachem Holding
7D
-10.7%
1Y
-18.2%

Bachem Holding (VTX:BANB) Ticks All The Boxes When It Comes To Earnings Growth

Sep 18
Bachem Holding (VTX:BANB) Ticks All The Boxes When It Comes To Earnings Growth
TECN
CHF 149.40
Tecan Group
7D
-5.7%
1Y
-45.8%
SFZN
CHF 78.20
Siegfried Holding
7D
-7.6%
1Y
-32.7%

Pharmaceutical Outsourcing And Supply Chain Resilience Will Drive Future Expansion

Siegfried Holding’s consensus analyst price target saw a marginal decrease to CHF110.67, as both revenue growth forecasts and discount rate assumptions remained effectively unchanged. What's in the News Siegfried Holding expects sales growth in the mid-single-digit percentage range in local currencies for 2025.
SKAN
CHF 53.50
SKAN Group
7D
-7.8%
1Y
-32.4%

US And Asian Expansion Will Unlock Pharmaceutical Market Potential

With no changes in key valuation metrics such as the discount rate (4.16%) and future P/E (28.70x), SKAN Group’s consensus analyst price target remains unchanged at CHF84.00. What's in the News SKAN Group AG confirmed its full-year 2025 earnings guidance, targeting sales growth in the mid-teens.